Page last updated: 2024-10-16

ammonium hydroxide and Heart Failure

ammonium hydroxide has been researched along with Heart Failure in 38 studies

azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"To assess the effects of dietary creatine supplementation on skeletal muscle metabolism and endurance in patients with chronic heart failure."9.08The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. ( Andrews, R; Cowley, AJ; Curtis, S; Greenhaff, P; Perry, A, 1998)
"Intravenous infusion of L-glutamic acid results in the augmentation of the cardiac output and an improvement of the circulation in patients with postoperative cardiac failure."7.67Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure. ( Ivanov, VE; Lepilin, MG; Pisarenko, OI, 1986)
"To assess the effects of dietary creatine supplementation on skeletal muscle metabolism and endurance in patients with chronic heart failure."5.08The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. ( Andrews, R; Cowley, AJ; Curtis, S; Greenhaff, P; Perry, A, 1998)
"Intravenous infusion of L-glutamic acid results in the augmentation of the cardiac output and an improvement of the circulation in patients with postoperative cardiac failure."3.67Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure. ( Ivanov, VE; Lepilin, MG; Pisarenko, OI, 1986)
"In the group of patients with ischemic heart disease and the group of heart transplant patients the flow errors were 10% (range 0%-55%, P<0."2.71Quantitation of the regional blood flow in the interventricular septum using positron emission tomography and nitrogen-13 ammonia. ( Freiberg, J; Gambhir, SS; Hove, JD; Kelbaek, H; Kofoed, KF, 2003)
"Advanced heart failure is associated with end-organ damage."1.42Clinical and prognostic role of ammonia in advanced decompensated heart failure. The cardio-abdominal syndrome? ( Bergerone, S; Botta, M; Bovolo, V; Canavosio, FG; Frea, S; Gaita, F; Pidello, S, 2015)
"A 23-year-old male patient with plasma cell leukemia showed characteristic clinical features: accelerating heart failure and consciousness disturbance accompanied with an increase of plasma cells in peripheral blood."1.29[Primary plasma cell leukemia complicated with high-output cardiac failure and hyperammonemia]. ( Hata, H; Kawaguchi, T; Kuribayashi, N; Matsuzaki, H; Nakahashi, E; Shimizu, K; Takatsuki, K; Tsuji, N, 1994)

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-199018 (47.37)18.7374
1990's7 (18.42)18.2507
2000's2 (5.26)29.6817
2010's7 (18.42)24.3611
2020's4 (10.53)2.80

Authors

AuthorsStudies
Yamamoto, A1
Nagao, M1
Kawakubo, M1
Ando, K1
Nakao, R1
Matsuo, Y1
Sakai, A1
Kaneko, K1
Momose, M1
Sakai, S1
Yamaguchi, J1
Miura, S1
Okizaki, A1
Manabe, O1
Miyazaki, C1
Yamashita, T1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J3
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Bing, OHL1
Monroy-Gonzalez, AG2
Tio, RA1
de Groot, JC1
Boersma, HH1
Prakken, NH1
De Jongste, MJL1
Alexanderson-Rosas, E1
Slart, RHJA2
Juarez-Orozco, LE1
van der Zant, FM1
Hoogvorst, N1
Knol, RJJ1
Hung, GU1
Zhou, W1
Tomiyama, T1
Kumita, S1
Ishihara, K1
Suda, M1
Sakurai, M1
Hakozaki, K1
Hashimoto, H1
Takahashi, N1
Takano, H1
Kobayashi, Y1
Kiriyama, T1
Fukushima, Y1
Shimizu, W1
Frea, S1
Bovolo, V1
Pidello, S1
Canavosio, FG1
Botta, M1
Bergerone, S1
Gaita, F1
Giannessi, D1
Caselli, C1
Del Ry, S1
Maltinti, M1
Pardini, S1
Turchi, S1
Cabiati, M1
Sampietro, T1
Abraham, N1
L'abbate, A1
Neglia, D1
Medeiros, WM1
Carvalho, AC1
Peres, P1
De Luca, FA1
Gun, C1
Hove, JD1
Gambhir, SS1
Kofoed, KF1
Freiberg, J1
Kelbaek, H1
BESSMAN, AN1
EVANS, JM1
SINGH, ID1
PRAKASH, C1
SACHDEVA, BS1
VICIU, E1
DULGHERU, C1
RUSSU, M1
CRISAN, A1
GANE, N1
BUSNEAG, C1
YILMAZ, S1
ACLAND, JD1
STRONG, R1
Steinmetz, AP1
Maisey, MN1
Hardoff, R1
RELMAN, AS1
EPSTEIN, FH1
Nakahashi, E1
Kuribayashi, N1
Tsuji, N1
Kawaguchi, T1
Hata, H1
Matsuzaki, H1
Shimizu, K1
Takatsuki, K1
Di Carli, MF1
Asgarzadie, F1
Schelbert, HR1
Brunken, RC1
Laks, H1
Phelps, ME1
Maddahi, J1
Ogino, K2
Osaki, S2
Kitamura, H1
Noguchi, N1
Hisatome, I2
Matsumoto, T1
Omodani, H1
Kato, M2
Kinugawa, T2
Miyakoda, H1
Kotake, H1
Mashiba, H1
Andrews, R2
Walsh, JT1
Evans, A1
Curtis, S2
Cowley, AJ2
Greenhaff, P1
Perry, A1
LekanneDeprez, RH1
van den Hoff, MJ1
de Boer, PA1
Ruijter, PM1
Maas, AA1
Chamuleau, RA1
Lamers, WH1
Moorman, AF1
Kato, T1
Endo, A1
Igawa, O1
Shigemasa, C1
Holmes, EW1
Pisarenko, OI1
Lepilin, MG1
Ivanov, VE1
Yoshida, K1
Himi, T1
Imai, H1
Shukuya, M1
Masuda, Y1
Inagaki, Y1
Yamasaki, T1
Tateno, Y1
Schrader, A1
Sidorenko, BA1
Kharchenko, VI1
Tol'stykh, AN1
Lewandowicz, J1
Mikuta, M1
Lewandowicz, H1
Valero, A1
Alroy, G1
Eisenkraft, B1
Itskovitch, J1
Ragusa, G1
Smilari, L1
Szám, I1
Vass, A1
Wein, I1
Tytman, B1
Bull, MB1
Laragh, JH1
Ito, H1
Cho, YW1
Aviado, DM1
Preuss, HG1
Davis, BB1
Maher, JF1
Bise, BW1
Schreiner, GE1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824]Phase 3321 participants (Actual)Interventional2015-11-15Completed
Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827]Phase 3865 participants (Actual)Interventional2005-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidence of Mortality

Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days

InterventionParticipants (Count of Participants)
Intravenous Glutamate Infusion1
Intravenous Saline Infusion6

Incidence of Unexpected Adverse Events

suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion

InterventionParticipants (Count of Participants)
Intravenous Glutamate Infusion0
Intravenous Saline Infusion0

Number of Participants With Incidence of Stroke

"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery

InterventionParticipants (Count of Participants)
Intravenous Glutamate Infusion0
Intravenous Saline Infusion4

Postoperative Increase of Plasma NT-proBNP

"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day

Interventionng/L (Mean)
Intravenous Glutamate Infusion5390
Intravenous Saline Infusion6452

Postoperative Increase of Plasma NT-proBNP in Patients Without Diabetes

"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day

Interventionng/L (Mean)
Intravenous Glutamate Infusion4503
Intravenous Saline Infusion6825

Postoperative Plasma Level of NT-proBNP

Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day

Interventionng/L (Mean)
Intravenous Glutamate Infusion4438
Intravenous Saline Infusion4420

Postoperative Plasma Level of NT-proBNP

Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day

Interventionng/L (Mean)
Intravenous Glutamate Infusion8055
Intravenous Saline Infusion8804

Atrial Fibrillation

Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay

InterventionParticipants (Count of Participants)
Intravenous Glutamate147
Saline Infusion152

ICU Stay

ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay

Interventionhours (Median)
Intravenous Glutamate21
Saline Infusion21

Number of Participants With Perioperative Myocardial Infarction, Postoperative Heart Failure or Postoperative Mortality

(NCT00489827)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Intravenous Glutamate31
Saline Infusion25

Number of Participants With Postoperative Stroke < 24 Hours

Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Intravenous Glutamate4
Saline Infusion6

Postoperative Hemodynamic State in Patients With Severely Reduced Left Ventricular Ejection Fraction (LVEF<0.40)

Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery

InterventionParticipants (Count of Participants)
Intravenous Glutamate1
Saline Infusion5

Postoperative Renal Function

maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days

Interventionµmol/L (Mean)
Intravenous Glutamate106
Saline Infusion106

Severe Circulatory Failure in CCS Class IV Patients

Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Intravenous Glutamate3
Saline Infusion16

Degree of Perioperative Myocardial Injury

p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative

,
Interventionµg/L (Median)
CK-MB day 1Troponin-T day 3
Intravenous Glutamate140.27
Saline Infusion140.24

Postoperative Hemodynamic State

Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU

,
Interventionpercentage of saturated hemoglobin (Mean)
SvO2 at weaning from CPBSvO2 on arrival to ICU
Intravenous Glutamate72.065.0
Saline Infusion72.264.9

Reviews

1 review available for ammonium hydroxide and Heart Failure

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016

Trials

5 trials available for ammonium hydroxide and Heart Failure

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
The dysfunction of ammonia in heart failure increases with an increase in the intensity of resistance exercise, even with the use of appropriate drug therapy.
    European journal of preventive cardiology, 2014, Volume: 21, Issue:2

    Topics: Adult; Ammonia; Biomarkers; Brazil; Cardiovascular Agents; Cross-Over Studies; Heart Failure; Humans

2014
Quantitation of the regional blood flow in the interventricular septum using positron emission tomography and nitrogen-13 ammonia.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:1

    Topics: Ammonia; Coronary Circulation; Female; Heart Failure; Heart Septum; Heart Transplantation; Heart Ven

2003
The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure.
    European heart journal, 1998, Volume: 19, Issue:4

    Topics: Aged; Ammonia; Cardiotonic Agents; Creatine; Dietary Supplements; Exercise Test; Exercise Tolerance;

1998
Altered purine and glycogen metabolism in skeletal muscle during exercise in patients with heart failure.
    Metabolism: clinical and experimental, 1999, Volume: 48, Issue:4

    Topics: Ammonia; Blood Pressure; Exercise; Exercise Test; Female; Glycogen; Heart Failure; Heart Rate; Human

1999

Other Studies

33 other studies available for ammonium hydroxide and Heart Failure

ArticleYear
Prediction of cardiovascular events using myocardial strain ratio derived from
    European radiology, 2023, Volume: 33, Issue:6

    Topics: Ammonia; Coronary Artery Disease; Fractional Flow Reserve, Myocardial; Heart Failure; Humans; Myocar

2023
Serial Quantitative Assessment of Myocardial Blood Flow With
    Circulation. Heart failure, 2023, Volume: 16, Issue:11

    Topics: Ammonia; Cardiomyopathies; Coronary Circulation; Heart Failure; Humans; Myocardial Perfusion Imaging

2023
Hypothesis: role for ammonia neutralization in the prevention and reversal of heart failure.
    American journal of physiology. Heart and circulatory physiology, 2018, 05-01, Volume: 314, Issue:5

    Topics: Ammonia; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Agents; Drug Therapy, Com

2018
Long-term prognostic value of quantitative myocardial perfusion in patients with chest pain and normal coronary arteries.
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2019, Volume: 26, Issue:6

    Topics: Adult; Ammonia; Chest Pain; Coronary Vessels; Female; Follow-Up Studies; Heart; Heart Failure; Human

2019
Ventricular synchrony is not significantly determined by absolute myocardial perfusion in patients with chronic heart failure: A
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2020, Volume: 27, Issue:6

    Topics: Aged; Ammonia; Body Mass Index; Coronary Angiography; Coronary Circulation; Female; Heart Failure; H

2020
A perfect tool for comprehensive evaluation of myocardial perfusion and function: Stress PET imaging.
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2020, Volume: 27, Issue:6

    Topics: Ammonia; Heart Failure; Humans; Nitrogen Radioisotopes; Perfusion; Positron-Emission Tomography

2020
Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in (13)N-ammonia PET studies.
    The international journal of cardiovascular imaging, 2015, Volume: 31, Issue:5

    Topics: Adenosine; Aged; Ammonia; Case-Control Studies; Chronic Disease; Coronary Artery Disease; Female; Fr

2015
Clinical and prognostic role of ammonia in advanced decompensated heart failure. The cardio-abdominal syndrome?
    International journal of cardiology, 2015, Sep-15, Volume: 195

    Topics: Abdominal Injuries; Aged; Ammonia; Biomarkers; Female; Heart Failure; Humans; Kidney; Male; Middle A

2015
Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:2

    Topics: Adiponectin; Ammonia; Body Mass Index; Cardiomyopathy, Dilated; Cholesterol, HDL; Cohort Studies; Co

2011
The blood ammonia in congestive heart failure.
    American heart journal, 1955, Volume: 50, Issue:5

    Topics: Ammonia; Blood; Heart Failure; Humans

1955
Blood ammonia level in congestive heart failure.
    The Indian journal of medical research, 1962, Volume: 50

    Topics: Ammonia; Heart Failure; Hematologic Tests; Humans

1962
[Functional examination of the liver in cardiac insufficiency. (Considerations on dysproteinemia, serum transaminases, ammonemia and other function tests)].
    Medicina interna, 1962, Volume: 14

    Topics: Ammonia; Blood Protein Disorders; Heart Failure; Humans; Liver; Liver Function Tests; Transaminases

1962
[ACTION OF AMMONIUM IN THE PATHOGENESIS OF CEREBRAL FUNCTIONS IN HEART FAILURE].
    Turk Tip Cemiyeti mecmuasi, 1964, Volume: 30

    Topics: Ammonia; Ammonium Compounds; Blood; Heart Failure; Hepatic Encephalopathy; Humans; Hypoxia, Brain; L

1964
PLASMA-AMMONIUM LEVELS IN CONGESTIVE CARDIAC FAILURE.
    Lancet (London, England), 1965, Aug-14, Volume: 2, Issue:7407

    Topics: Ammonia; Ammonium Compounds; Blood; Heart Failure; Humans

1965
Patterns of papillary muscle ischemia in myocardial PET.
    Clinical nuclear medicine, 2004, Volume: 29, Issue:1

    Topics: Ammonia; Cardiomyopathies; Female; Fluorodeoxyglucose F18; Heart Failure; Humans; Male; Middle Aged;

2004
Effect of tetraethylammonium on venous and arterial pressure in congestive heart failure.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1949, Volume: 70, Issue:1

    Topics: Ammonia; Ammonium Compounds; Arterial Pressure; Blood Pressure; Dermatologic Agents; Heart Failure;

1949
[Primary plasma cell leukemia complicated with high-output cardiac failure and hyperammonemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:8

    Topics: Adult; Ammonia; Antineoplastic Combined Chemotherapy Protocols; Cardiac Output; Dexamethasone; Doxor

1994
Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy.
    Circulation, 1995, Dec-15, Volume: 92, Issue:12

    Topics: Aged; Ammonia; Coronary Artery Bypass; Coronary Disease; Deoxyglucose; Exercise Tolerance; Female; F

1995
Ammonia response to exercise in patients with congestive heart failure.
    Heart (British Cardiac Society), 1996, Volume: 75, Issue:4

    Topics: Adenosine Triphosphate; Ammonia; Exercise; Exercise Test; Female; Heart Failure; Humans; Hypoxanthin

1996
Abnormalities of skeletal muscle metabolism in patients with chronic heart failure: evidence that they are present at rest.
    Heart (British Cardiac Society), 1997, Volume: 77, Issue:2

    Topics: Adult; Aged; Ammonia; Female; Forearm; Hand Strength; Heart Failure; Humans; Lactic Acid; Male; Midd

1997
Changing patterns of gene expression in the pulmonary trunk-banded rat heart.
    Journal of molecular and cellular cardiology, 1998, Volume: 30, Issue:9

    Topics: Ammonia; Animals; Atrial Natriuretic Factor; Biomarkers; Blotting, Northern; Calcium-Binding Protein

1998
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
    Clinical science (London, England : 1979), 1986, Volume: 70, Issue:1

    Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody

1986
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
    Clinical science (London, England : 1979), 1986, Volume: 70, Issue:1

    Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody

1986
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
    Clinical science (London, England : 1979), 1986, Volume: 70, Issue:1

    Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody

1986
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
    Clinical science (London, England : 1979), 1986, Volume: 70, Issue:1

    Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody

1986
[Positron computed tomography for myocardial uptake of N-13 ammonia in patients with hypertrophic cardiomyopathy: a preliminary study].
    Journal of cardiography, 1985, Volume: 15, Issue:2

    Topics: Adult; Ammonia; Cardiomyopathy, Hypertrophic; Female; Heart Failure; Heart Ventricles; Humans; Male;

1985
[Parenchymatous organs, hematopoietic system].
    Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete, 1971, Volume: 29, Issue:1

    Topics: Ammonia; Anemia; Blood Coagulation Disorders; Brain; Brain Diseases; Brain Edema; Cerebral Hemorrhag

1971
[Use of saluretic preparation hygrotone for the treatment of patients with chronic circulatory insufficiency].
    Kardiologiia, 1974, Volume: 14, Issue:7

    Topics: Adult; Aged; Ammonia; Chlorthalidone; Chronic Disease; Diuresis; Female; Glomerular Filtration Rate;

1974
[Level of blood ammonia in chronic congestive circulatory failure].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1974, Dec-16, Volume: 29, Issue:50

    Topics: Adult; Aged; Ammonia; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Time Factor

1974
Ammonia metabolism in chronic obstructive pulmonary disease with special reference to congestive right ventricular failure.
    Thorax, 1974, Volume: 29, Issue:6

    Topics: Acid-Base Equilibrium; Adolescent; Adult; Aged; Ammonia; Carbon Dioxide; Cerebrovascular Disorders;

1974
[Behavior of ammoniemia during treatment with ethacrynic acid in cardiopathic patients with congestive circulatory failure].
    Bollettino della Societa italiana di cardiologia, 1972, Volume: 17, Issue:7

    Topics: Ammonia; Ethacrynic Acid; Heart Diseases; Heart Failure; Humans

1972
Hyperammonemia in cor pulmonale.
    Cardiologia, 1969, Volume: 54, Issue:6

    Topics: Acidosis; Aged; Ammonia; Brain Diseases; Cardiac Glycosides; Diuretics; Heart Failure; Heart Ventric

1969
[Test of provoked hyperammonemia in chronic cor pulmonale].
    Polskie Archiwum Medycyny Wewnetrznej, 1970, Volume: 44, Issue:3

    Topics: Ammonia; Ammonium Chloride; Chronic Disease; Heart Failure; Humans; Liver; Pulmonary Heart Disease

1970
Amiloride. A potassium-sparing natriuretic agent.
    Circulation, 1968, Volume: 37, Issue:1

    Topics: Acetazolamide; Aldosterone; Ammonia; Ascites; Bicarbonates; Blood Pressure; Chlorides; Chlorothiazid

1968
Comparative effects of digoxin and proscillaridin in the heart-lung preparation.
    Diseases of the chest, 1969, Volume: 56, Issue:1

    Topics: Ammonia; Animals; Blood Flow Velocity; Cardiac Glycosides; Cardiac Output; Coronary Vessels; Digoxin

1969
Ammonia metabolism in renal failure.
    Annals of internal medicine, 1966, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Ammonia; Blood Gas Analysis; Blood Urea Nitrogen; Female; Heart Failure; Humans;

1966